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Objectives:Extended-spectrumb-lactamase-producingEnterobacteriaceae (ESBL-E)arean increasingly frequent
cause of infections in the community and the healthcare setting. In this study, we aimed to investigate whether
intestinal carriage of ESBL-E can be eradicated.
Methods:Weconducted a double-blind, randomized, placebo-controlled, single-centre trial to assess the efficacy
of an oral decolonization regimen on intestinal ESBL-E carriage in adult patients with an ESBL-E-positive rectal
swab. Fifty-eight patients were allocated 1:1 to either placebo or colistin sulphate (50 mg 4×/day) and neomycin
sulphate (250 mg 4×/day) for 10 days plus nitrofurantoin (100 mg 3×/day) for 5 days in the presence of ESBL-E
bacteriuria. The primary outcomewas detection of ESBL-E by rectal swab 28+7 days after the end of treatment.
Missing primary outcome data were imputed based on the last available observation. Additional cultures (rectal,
inguinal and urine) were taken on day 6 of treatment and on days 1 and 7 post-treatment. The study protocol has
been registered with ClinicalTrials.gov (NCT00826670).
Results:Among54patients (27 ineachgroup) included in theprimaryanalysis, therewasnostatisticallysignificant
difference between the groups with regard to the primary outcome [14/27 (52%) versus 10/27 (37%), P¼0.27].
During treatment and shortly afterwards, there was significantly lower rectal ESBL-E carriage in the treatment
group: 9/26 versus 19/22 on day 6 of treatment (P,0.001) and 8/25 versus 20/26 on day 1 post-treatment
(P¼0.001). This effect had disappeared by day 7 post-treatment (18/27 versus 17/25, P¼0.92). Liquid stools
were more common in the treatment group (7/27 versus 2/29, P¼0.05).
Conclusions: The regimen used in this study temporarily suppressed ESBL-E carriage, but had no long-term effect.
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Introduction
Intestinal carriage of extended-spectrum b-lactamase-producing
Enterobacteriaceae (ESBL-E) has become common inmany coun-
tries.1,2 While ESBL-E carriage often persists for years without
disease, these bacteria can occasionally cause bloodstream and
urinary tract infections even in patients without discernible
healthcare-associated risk factors.3–8
Examining methods to decolonize ESBL-E carriers as a preven-
tion strategy seems warranted, given the risk of subsequent inva-
sive infection in ESBL-E carriers, the fact that carriers are a
potential source of cross-transmission, the potential for chronic
carriage and the possibility of horizontal gene transfer conferring
resistance to other bacteria in the intestinal tract.9 Since the intes-
tinal tract is themain reservoir for ESBL-E, non-absorbed oral anti-
biotics without activity against the anaerobic microflora, such as
aminoglycosides and polymyxins, are promising treatment
options. Theseagentshavebeenusedwidely for selectivedigestive
decontamination in patients undergoing chemotherapy or intes-
tinal surgery and in critically ill patients, and are generally well tol-
erated.10–12
While decolonization regimens have been extensively studied
for Gram-positive bacteria such as Staphylococcus aureus, only a
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few studies have examined theeffect of decolonization attempts on
ESBL-E carriage.13 Most of these studies were uncontrolled and had
important methodological limitations.14–17 To our knowledge, no
randomized, placebo-controlled clinical trial has been conducted
to study the efficacy of a systematic ESBL-E eradication strategy.
Eradication or suppression of ESBL-E carriage would theoretically
be beneficial for both the individual patient and the community.
However, the emergence of resistance to decolonization agents is
a potential concern that needs to be monitored.18 We performed
an investigator-initiated, double-blind, placebo-controlled study to
evaluate the efficacyandsafetyof anoral courseof colistin andneo-
mycin for 10 days (with nitrofurantoin in the case of ESBL-E bacteri-
uria) to suppress asymptomatic gastrointestinal ESBL-E carriage.
Methods
Trial design
This was a double-blind, placebo-controlled, parallel-group study with
balanced (1:1) randomization. The study protocol was approved by the
local institutional review board (IRB) (no. 08-161) and the Swiss agency
for therapeutic products (SwissMedic no. 2009DR2087) andhas been regis-
teredwithClinicalTrials.gov (NCT00826670).Written informedconsentwas
obtained from all participants.
With regard to changes to methods after trial commencement, a posi-
tive urine culturewith ESBL-Ewas initially considered anexclusion criterion.
Due to slow recruitment, the protocol was, however, amended and from
January 2010 onwards this was no longer an exclusion criterion except in
the context of a urinary catheter that could not be changed.
Participants
Enrolment occurred between June 2009 and June 2012. Patients aged
≥18 years with an ESBL-E-positive rectal swab and the ability to provide
informed consent were eligible. An automatic alert system identifies all re-
admitted patients with a history of ESBL-E carriage at Geneva University
Hospitals (HUG).19 Active screening for ESBL-E carriage was limited to
these ‘alert’ patients and certain pre-defined risk groups, such as patients
transferred from abroad or patients having shared a room with newly
detected ESBL-E carriers.20 Patients with active ESBL-E infection and
patients treatedwith antibiotics active against ESBL-Ewere excluded. Add-
itional exclusion criteria were pregnancy/breastfeeding, contraindications
to the use of the study drugs, previous study enrolment and resistance of
the colonizing ESBL-E strain to colistin (defined as MIC.2 mg/L).
The study was conducted in all inpatient wards of HUG, a tertiary care
centre with 1915 beds and48000 yearly admissions in Switzerland.
Interventions
Patients randomized to the treatment arm received oral colistin sulphate
(50 mg equivalent to 42 mg colistin base or 1.26 million units 4×/day)
and oral neomycin sulphate (250 mg equivalent to 178 mg neomycin
base 4×/day) for 10 days. In the presence of ESBL-E bacteriuria, oral nitro-
furantoin (100 mg 3×/day) was added during the first 5 days. Patients in
the control group receivedplacebodrugswith the same frequencyanddur-
ation of administration.
Outcomes
Patients were assessed at baseline, on day 6 of treatment and on days 1, 7
and 28 after the end of treatment. At each visit, rectal swabs were per-
formedby inserting a pre-moistened swab3–4 cmpast the anal sphincter,
rotating the swab 3608 and then inserting the swab immediately in culture
media. In addition, both inguinal folds were swabbed with a second pre-
moistened swab. All patients provided a midstream urine sample at base-
line and at the final follow-up visit. The pre-defined primaryoutcomeof the
studywasthedetectionof intestinal ESBL-Ecarriagebya rectal swabduring
day 28+7 post-treatment. Secondaryoutcomeswere safetyand tolerabil-
ityof thestudy regimen,detectionof rectal, urinaryand inguinalESBL-Ecar-
riage during the other study visits, and change in colistin MICs between
baseline and the final visit. Poor treatment compliance was defined as
.20% of any of the study medication remaining in the study drug box
when returned by the patient.
Screening for ESBL-Ewasperformedusingaselective chromogenicagar
(BLSE-ID, bioMe´rieux, Marcy l’E´toile, France). Bacterial identification was
based on the colour of the colonies with subsequent confirmation by
matrix-assisted laser desorption ionization time-of-flight mass spectrom-
etry (MALDI-TOF MS; Bruker Daltonics, Billerica, MA, USA). ESBL production
was confirmed by the double-disc synergy test. Until October 2011, four
discs were used: cefotaxime, cefotaxime/clavulanic acid, ceftazidime and
ceftazidime/clavulanic acid. Thepresenceof ESBLwas confirmedwhenever
the inhibition zone was ≥5 mm larger with the antibiotic/clavulanic acid
combination than with the antibiotic alone, confirming synergy. From
October 2011, only two discs were used: cefepime (30 mg) and cefepime/
clavulanic acid deposited 20 mm apart on a Mueller–Hinton agar plate.
The presence of ESBL was confirmed whenever synergy was observed (in-
hibition zone increased by ≥5 mm). Susceptibility testing was performed
using commercial panels and CLSI criteria (disc diffusion test for
nitrofurantoin and Etest for colistin).21,22 Neomycin MICs were determined
as recommended post hoc for available baseline and day 28 post-
treatment samples in the colistin/neomycin group and for a convenience
sample of 17 patients in the placebo group (baseline only).23
Sample size
Based on our own experience, we assumed that 30% of patients would
clear ESBL-E colonization spontaneously within 28 days and hypothesized
that a decolonization regimen would be clinically useful if able to clear col-
onization inanadditional 40%ofpersons.Usinga two-sidedaof0.05anda
b of 0.2, we calculated a sample size of 29 patients in each group.
Randomization
The randomization sequencewasgenerated by the studypharmacistusing
an internet-based randomization plan generatorwith a constant block size
of 10. Based on the randomization sequence, containers with the study
drugs were sequentially numbered and participants were given containers
in numerical order. Participants were enrolled by the physicians that were
part of the study team.
Blinding
The study pharmacist was the only individual aware of the treatment allo-
cation and was not involved in the study conduct or analysis. The placebo
capsules contained mannitol and were indistinguishable from the test
medicationwith regard tocolour, sizeand form. Participants, careproviders
and those assessing outcomes were blinded to the treatment allocation.
The success of blinding was not formally assessed.
Statistical methods
The primary analysis was a modified intention-to-treat analysis that
excluded patients with no follow-up visit or a baseline rectal swab that
was either negative or not performed. In the case of missing primary
outcome data (e.g. due to loss to follow-up) or in the case of a final study
visit that was performed either too late or too early (i.e. ,21 days or
.35 days after the end of the decolonization regimen), we imputed the
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primaryoutcomebasedon the last available observation. Since imputation
of missing outcomesmay lead to biased results, we also performed a sen-
sitivityanalysiswherebypatientswithfinalassessmentearlier than21 days
after the endof treatmentwere assigned anegative final rectal swab in the
placebo group (since there is spontaneous loss of carriage over time) and a
positive rectal swab in the treatment group (in case of a rebound effect). In
addition, patients in the treatmentgroupwithafinal assessment later than
35 days and/or treated with antibiotics active against ESBL-E were consid-
ered to have failed eradication.
Secondary outcomemeasures were evaluated including all participants
withevaluabledataateachrespectivestudyvisit.All patientshaving received
at least one dose of the study drug were included in the analysis of adverse
effects. Differences in ESBL-E carriage between the study groups were
analysed by the x2-test or Fisher’s exact test, as appropriate. Univariate
logistic regression was used to determine the OR for the presence of
ESBL-E in the treatment group. The Wilcoxon signed-rank test was used to
assess changes in colistin and neomycin MICs. All tests were two-tailed
with a P value,0.05 considered statistically significant. Statistical analyses
wereperformedusingSTATAversion12(StataCorp., CollegeStation,TX,USA).
Results
Participant flow and recruitment
The study flowchart is shown in Figure 1. Therewere 1281 patients
with known current or past ESBL-E colonization at HUG between
June 2009 and June 2012. Of these, 139 (10.9%) were deemed
1281 patients
with current or past ESBL-E colonization
screened between 06/2009 and 06/2012
82 patients
signed informed consent
58 patients
randomized
29 patients
colistin/neomycin
(12 nitrofurantoin)
29 patients
placebo
(7 nitrofurantoin placebo)
2 patients excluded
did not fulfill inclusion criteria
2 patients excluded
no single follow-up visit
27 patients Population for
primary analysisplacebo
(7 nitrofurantoin placebo)
Protocol violations
4 patients ﬁnal visit too early
3 patients ﬁnal visit too late
5 patients treated with anti-ESBL
antibiotic
Protocol violations
1 patient ﬁnal visit too early
1 patient ﬁnal visit too late
1 patient treated with anti-ESBL
antibiotic
27 patients
colistin/neomycin
(12 nitrofurantoin)
1199 patients excluded
•  587 > 1 exclusion criterion present
•  555 not hospitalized or discharged before
    being contacted
•  57 study proposed but no consent
24 patients excluded
•  11 baseline rectal swab negative
•  7 urinary colonization before protocol
    amendment
•  4 withdrew consent before randomization
•  2 urinary colonization and
    contraindication to nitrofurantoin
Figure 1. Trial profile.
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to be eligible after chart review and were invited to participate.
Eighty-two (6.4%) agreed to participate in the study and provided
written consent. After the exclusion of 24 patients thatwere found
not to meet the inclusion criteria after baseline assessment, 29
patients were randomized to each study arm.
Baseline data
The two study groups had similar baseline clinical and demographic
characteristics (Table 1). The mean age of participants was
54.5 years (range 19–81 years); 34/58 (58.6%) were male. More
patients in the treatment group had bacteriuria (12/29 versus 7/29).
Half of all patients had inguinal carriage at baseline. Escherichia
coli was the predominant intestinal ESBL-E species, detected in
47/58 (81.0%) patients.
Numbers analysed
Of the 58 patients, 2 (both in the treatment group) withdrew
consent after randomization but before treatment start and
were therefore excluded from further analysis. An additional two
patients (both in the placebo group) were erroneously randomized
based on ESBL-E carriage detected by stool culture (one had a
negative rectal swab at baseline and one had no rectal swab per-
formed). Both were excluded from the analysis of the primary
outcome but were included in the other analyses. Twenty-seven
patients in each group were included in the primary analysis. Of
these, seven participants in the placebo group (two lost to follow-
up, onewithdrawal of consent and refusal of further follow-up and
four logistic reasons) and two in the treatment group (one lost to
follow-up and one logistic reasons) had a final assessment that
was performed either too early or too late (Figure 1). For these
patients, the primary outcome was imputed based on the last
available result.
Outcomes and estimation
In the primary analysis, 14 of 27 patients (51.9%) in the treatment
group and 10 of 27 (37.0%) in the placebo group had eradicated
ESBL-E carriage, a difference that was not statistically significant
(OR 0.55, 95%CI 0.18–1.62). The conservative sensitivity analysis,
whichassignedadifferentoutcome for fourpatients in theplacebo
group (sincefinal analysiswas tooearly) and for twopatients in the
treatment group (onewith afinal analysis performed too earlyand
one treated with fosfomycin) confirmed the absence of an effect
(OR 1.35, 95% CI 0.46–3.93).
Figure 2 displays the evolution of ESBL-E carriage over time,
according to the carriage sites at baseline. On day 6 of treatment,
rectal carriage of ESBL-E was significantly lower in the treatment
group than in the placebo group (9/26 versus 19/22, P,0.001).
This difference persisted until the visit 1 day after the end of treat-
ment (8/25 versus 20/26, P¼0.001), but had disappeared by the
next visit at day 7 after the end of treatment (18/27 versus 17/25,
P¼0.92). There was no significant difference in inguinal carriage
between thegroupsat anystudyvisit. Therewasalsono significant
effect on bacteriuria with ESBL-E at any study visit in the subgroup
of patients with bacteriuria at baseline.
Harms
Sevenoutof27(25.9%)patients inthetreatmentgroup(versus2/29
in the placebo group, P¼0.05) with at least one follow-up visit
reported at least one episode of liquid stools. Two of these patients
stoppedtreatmentprematurely.A totalof sixpatientswere treated
with antibiotics with activity against the colonizing ESBL-E strain
before the end of follow-up (five in the placebo group and one in
the treatment group).
Table 1. Baseline demographics and microbiological results by group (all
randomized patients)
Colistin/neomycin
group (n¼29)
Placebo group
(n¼29)
Male, n (%) 18 (62.1) 16 (55.2)
Age (years), median (IQR) 51 (38–67) 61 (48–69)
Duration of known ESBL-E
carriage at inclusion
(days), median (IQR)
7 (6–21) 11 (7–54)
BMI (kg/m2), median (IQR) 26.1 (23.3–28.4) 26.1 (23.1–29.0)
Comorbidities, n (%)
cardiovascular disease 5 (17.2) 6 (20.7)
COPD 2 (6.9) 6 (20.7)
diabetes 6 (20.7) 6 (20.7)
chronic liver disease 1 (3.5) 2 (6.9)
neoplastic disease 1 (3.5) 1 (3.5)
immunosuppressive
treatment
4 (13.8) 2 (6.9)
inflammatory bowel
diseases
0 0
ESBL-E species at baseline rectal swab, n
Escherichia coli 25 20
Klebsiella pneumoniae 9 5
Klebsiella oxytoca 1 0
Citrobacter freundii 0 1
Enterobacter cloacae 2 2
Enterobacter asburiae 0 1
none/unknowna 2 0
Two species at baseline
rectal swab, n (%)
8 (27.6) 2 (6.9)
Site of ESBL-E colonization at baseline, n (%)
rectala 27 (93.1) 29 (100)
inguinal 15 (51.7) 14 (48.3)
urine 12 (41.4) 7 (24.1)
Baseline colistin MIC
(mg/L)b, median (IQR)
0.190 (0.125–0.380) 0.125 (0.125–0.250)
Baseline neomycin MIC
(mg/L), median (IQR)
2 (2–32) 2c (2–32)
BMI, body mass index; COPD, chronic obstructive pulmonary disease.
aTwo patients had positive stool cultures with ESBL-producing E. coli. One
patienthadanegative rectalbaselineswabandonehadnorectal swabper-
formed.
bIn caseofmore thanoneESBL-Especies in the same individual, thehighest
MICwas chosen.
cConvenience sample of 17/29 patients from the control group.
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All ESBL-E isolates recovered during the study were susceptible
to carbapenems. There was no statistically significant change in
colistin or neomycin MICs between baseline and the final ESBL-E
culture in the treatment group (Figure 3). In addition, with the ex-
ception of one isolate of an intrinsically colistin-resistant species
(Morganella morganii), no colistin resistance was detected in the
treatment group during follow-up.
Treatment adherence
Boxes of study medication could be recuperated for 41 (71%)
patients. All 18 patients in the placebo group with recuperated
boxes fulfilled criteria for adherence. Of the 22 patients in the treat-
ment group that had taken at least one dose of study medication
with recuperated boxes, 3 patients had.20%of the studymedica-
tion left, ofwhom2hadstopped treatmentprematurely (seeabove).
Discussion
This randomized, controlled trial of an oral decolonization regimen
demonstrated a substantial temporary suppression of intestinal
ESBL-E carriage during treatment, with no sustained effect after
4 weeks.
Previous studies
To our knowledge, we report the first randomized, controlled trial
examining a decolonization strategy for carriers of ESBL-E. An
Israeli study examined the effectiveness of selective digestive
decontamination for eradicating carriage of carbapenem-resistant
Klebsiella pneumoniae (CRKP).24 The interpretationof this study that
reported a reduction in CRKP-positive rectal swabs at weeks 2 (16%
versus 61%) and 6 (33%versus 59%) ismade difficult bymethodo-
logical limitations, and the fact that 9/40 patients died.
Anotherarticle reported theexperiencewithESBL-Edecoloniza-
tion at the University Hospital Basel between 2000 and 2008.25 In
this uncontrolled case series, all patients with documented ESBL-E
colonization were offered a regimen consisting of chlorhexidine
mouth rinse in case of throat colonization, oral paromomycin in
case of intestinal colonization and oral antibiotics in case of bac-
teriuria. Of the 35 patients with available follow-up data, 63%
were free of ESBL at the last follow-up performed. This percentage
was, however, not significantly different from the 18 patients that
did not receive decolonization treatment.
Several older studieshave reported theuseofdifferentdecolon-
ization regimens inESBL-Eoutbreakswithmixed results.14–17Since
the interpretationof these studies is hamperedby theirweak study
design, limited generalizability and very short follow-up periods, a
detailed discussion is beyond the scope of this article.
Extraintestinal colonization
Inour study, thepercentageofpatientswith inguinal ESBL-Ecolon-
ization was 50% at baseline. This is similar to findings from two
other Swiss hospitals.26,27 It remains unclear if the skin represents
a separate reservoir for ESBL-E and if adding a skin disinfectant to
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Figure2. EvolutionofESBL-Ecarriageover timewith regard to (a)anyESBL-Ecarriage, (b) rectal ESBL-Ecarriage, (c) inguinalESBL-Ecarriageand (d)urinary
ESBL-Ecarriage.All graphsexclude twopatients in theplacebogroupwithouta single follow-upvisit. Studyvisits are reportedwith the scheduledvisit date,
even if done early or late. Graphs (a), (b) and (c) include all available data at each study visit. Graph (d) only includes participants with urinary ESBL-E
colonization at baseline. Treatment, dark grey circles; placebo, light grey triangles. bl, baseline; d6t, day 6 of treatment; d1, day 1 post-treatment; d7,
day 7 post-treatment; d28, day 28 post-treatment.
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the decolonization regimen may provide any additional benefit.
Pharyngeal carriage of ESBL-E has also been described and may
yet represent a further reservoir.28
Colistin resistance
We did not observe statistically significant changes in the mea-
sured colistin MIC values between the initial and final isolates,
and no acquired colistin resistance was documented in isolates
obtained during follow-up.
Limitations and generalizability
First, we deviated from the intention-to-treat principle in our ana-
lyses by excluding four patients after randomization.29 We have,
however, no reason to suspect that themotives for the exclusions
were related inanyway togroupassignment. Second, theadminis-
tered dose of 1 g of neomycin sulphate per day was relatively low
comparedwith the 3–4 g per day commonly used in pre-operative
bowel preparation.10 Other centres, however, have used doses
similar to ours for selective gut decontamination.30 Third, rectal
swabs may be inadequate to detect resistant pathogens present
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Figure 3. Colistin and neomycin MICs at baseline and at the final [day 28 post-treatment (d28)] study visit by treatment group. Graphs only include
instances where the same ESBL-E was recovered on rectal swabs or stool cultures at baseline and at the final study visit and where a colistin MIC was
determined at both visits. bl, baseline.
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in small amounts and stool cultures may have given different
results.31 Anegative rectal swabmay therefore reflect suppression
of ESBL-E colonies below the detection level rather than complete
eradication of ESBL-E carriage. In addition, the absence of growth
onselective chromogenic agarduring treatmentmaybedue to the
inhibitory effect of the antibiotics (rather than the absence of
ESBL-E). Fourth, the trial was underpowered to detect clinically sig-
nificantdifferencesbetweenthe treatmentarmsthatwere smaller
than those postulated for the sample size calculation. Fifth, we
were unable to differentiate rebound of colonization from exogen-
ous reacquisition of ESBL-E strains. Finally, the external validity of
this trial may be limited given its single-centre setting and highly
selected patient population.
Interpretation
Intestinal ESBL-E carriage is a risk factor for subsequent bacter-
aemia and invasive urinary tract infection, particularly among
high-risk patients.32 Temporary suppression of ESBL-E carriage
could add a clinical benefit in high-risk patients. Thus, a strategy
of early detection and suppression of ESBL-E in colonized high-risk
patients during prolonged periods of immunosuppression or de-
rangement of gastrointestinal mucosal integrity could result in a
reduction in the incidence of subsequent ESBL-E bloodstream
infections. A largemulticentre trialwouldbeneeded to test this hy-
pothesis. The increasing frequencyofESBL-Ecarriage in thegeneral
population, possibly mediated by contaminated food, likely
renders a widespread decolonization policy for ESBL carriers un-
feasible.33,34 Furthermore, the long-term impact of decolonization
regimenson the intestinalmicrobiomeandtheemergenceof colis-
tin resistance merit further investigation.35
Conclusion
This study did not demonstrate an effect of an oral antibiotic
regimen containing colistin and neomycin, with nitrofurantoin in
presence of bacteriuria, on rectal ESBL-E carriage 28 days after
the end of treatment. We observed a temporary suppression of
ESBL-E carriage during treatment and immediately afterwards,
with rapid rebound 1 week after the end of treatment. Future
studies should attempt to define patient populations at high risk
of infection or pathogens at high risk of cross-transmission,
where this transienteffectmaybebeneficial.Additionally, different
strategies warrant investigation, such as administering probiotics
at the conclusion of the decolonization regimen.
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